ArticleScientific reports2025
Neuroform EZ stenting for basilar artery atherosclerotic stenosis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Periprocedural complications, including perforator occlusion, in-stent restenosis, and even death, are frequently encountered in endovascular therapy for basilar artery (BA) lesions. This study sought to evaluate the efficacy of the Neuroform EZ stent in managing atherosclerotic BA stenosis. A retrospective analysis was conducted on clinical data from 71 patients with symptomatic atherosclerotic BA stenosis who underwent Neuroform EZ stent implantation. The primary outcomes assessed were periprocedural complications (ischemic stroke, death, restenosis, or hemorrhagic stroke) within 30 days post-surgery. Additionally, multivariable logistic regression analysis was used to identify risk factors for in-stent restenosis (ISR). Results showed that the mean stenosis degree significantly improved from 85.2% ± 8.7% before treatment to 25.8% ± 12.5% after Neuroform EZ stent placement. Furthermore, the mean NIHSS score decreased by 3 points following the procedure. The overall ISR rate among all patients was 6.5%. Multivariable logistic regression analysis revealed that irregular post-procedural antiplatelet therapy (HR, 3.231; 95% CI, 1.09-4.61; p = 0.031), lesion length (HR, 2.966; 95% CI, 1.21-4.23; p = 0.026), and lesion location (HR, 3.117; 95% CI, 1.12-4.15; p = 0.042) were independent risk factors for long-term ISR. In conclusion, this study provides evidence supporting the effective use of the Neuroform EZ stent in the treatment of refractory BA stenosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.